Agilon Health Inc. (AGL) Reports In-Line Q2 EPS; lowers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
agilon health Inc (AGL) PT Lowered to $4 at Deutsche Bank
August 8, 2024 4:08 PM EDTDeutsche Bank analyst George Hill lowered the price target on agilon health Inc (NYSE: AGL) to $4.00 (from $5.00) while maintaining a Hold rating.
The analyst comments "Another Revenue Miss: AGL reported Q2 results missing at the revenue line but making it up with the better-than-expected adjusted EBITDA. AGL reported total revenue of $1.48B (+38% yoy), below the... More
